公开(公告)号：US20160243215A1

公开(公告)日：2016-08-25

申请号：US15026391

申请日：2014-10-03

申请人： BETH ISRAEL DEACONESS MEDICAL CENTER, INC.

发明人： Dan H. BAROUCH ,  Christine BIRCAULT

IPC分类号： A61K39/21 ,  C12N7/00

摘要： The invention features stabilized human immunodeficiency virus (H IV) clade C envelope (Env) trimers. The invention also features vaccines, nucleic acids, and vectors to deliver and/or facilitate production of the stabilized HIV clade C Env trimers. In addition, the invention features methods of making and using the stabilized HIV clade C Env trimers of the invention.

摘要翻译： 本发明具有稳定的人类免疫缺陷病毒（H IV）进化枝C包膜（Env）三聚体。 本发明还具有用于递送和/或促进稳定的HIV进化枝C Env三聚体的生产的疫苗，核酸和载体。 此外，本发明的特征在于制备和使用本发明的稳定的HIV进化枝C Env三聚体的方法。

公开(公告)号：US20160213779A1

公开(公告)日：2016-07-28

申请号：US15025961

申请日：2014-09-30

申请人： Beth Israel Deaconess Medical Center, Inc.

发明人： Dan H. BAROUCH

IPC分类号： A61K39/42 ,  A61K45/06 ,  A61K39/395 ,  C07K16/10

CPC分类号： A61K39/42 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  A61K2039/507 ,  C07K16/1045 ,  C07K16/1063 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/94

摘要： This invention relates to antibody therapies for human immunodeficiency virus (HIV). In particular, the invention provides methods of curing subjects infected with HIV and blocking HIV infections in subjects at risk of HIV transmission using a N332 glycan-dependent antibody (e.g., PGT121).

摘要翻译： 本发明涉及用于人类免疫缺陷病毒（HIV）的抗体疗法。 特别地，本发明提供了使用N332聚糖依赖性抗体（例如，PGT121）来治疗HIV感染的受试者和HIV传播风险的受试者中的HIV感染的方法。

公开(公告)号：US20220401542A1

公开(公告)日：2022-12-22

申请号：US17774385

申请日：2020-11-05

申请人： Beth Israel Deaconess Medical Center, Inc.

发明人： Dan H. BAROUCH ,  Amanda J. MARTINOT

IPC分类号： A61K39/04 ,  C12N1/20 ,  C12N1/36 ,  G01N33/68 ,  A61P31/06

摘要： Disclosed herein are immunogenic compositions (e.g., vaccines) for use in the treatment of mycobacteria infections and biomarkers for monitoring of therapeutic responsiveness to the immunogenic compositions in a subject (e.g., a human). In a first aspect, the disclosure features a pharmaceutical composition containing between 1×10{circumflex over ( )}2 CPU and 1×10{circumflex over ( )}10 CPU of a Mycobacterium tuberculosis strain (Mtb) with one or more mutations that ablate or reduce expression of LprG and Rv1410 (ΔLprG Mtb) in a volume of between 0.05 mL and 3 mL.

公开(公告)号：US20220025021A1

公开(公告)日：2022-01-27

申请号：US17295798

申请日：2019-11-19

申请人： Beth Israel Deaconess Medical Center, Inc.

发明人： Dan H. BAROUCH ,  Bruce A. KERWIN ,  Randal R. KETCHEM ,  Alison J. GILLESPIE ,  Christine C. SISKA ,  Rutilio H. CLARK ,  Julee A. FLOYD ,  Jeremy M. SHAVER

IPC分类号： C07K16/10 ,  A61K45/06

摘要： Featured are PGDM1400 variant antibodies or fragments thereof, which can be administered, e.g., as antibody therapies for treating human immunodeficiency virus (HIV) infection. In particular, featured are methods of treating or curing subjects infected with HIV and/or preventing HIV infections in subjects at risk of HIV transmission using the PGDM1400 variant antibodies or fragments thereof.

公开(公告)号：US20210388032A1

公开(公告)日：2021-12-16

申请号：US17387105

申请日：2021-07-28

申请人： Janssen Pharmaceuticals, Inc. ,  Beth Israel Deaconess Medical Center, Inc.

发明人： Johannes Petrus Maria LANGEDIJK ,  Lucy RUTTEN ,  Mark Johannes Gerardus BAKKERS ,  Rinke BOS ,  Frank WEGMANN ,  David Adrianus Thedorus Maria ZUIJDGEEST ,  Dan H. BAROUCH ,  An VANDEBOSCH ,  Mathieu Claude Michel le GARS ,  Jerald C. SADOFF

IPC分类号： C07K14/005 ,  A61P31/14 ,  C12N7/00 ,  C12N15/86 ,  A61K39/215

摘要： The invention relates to immunogenic compositions and vaccines containing a coronavirus (e.g., Wuhan coronavirus (2019-nCoV; also referred to as SARS-CoV-2)) protein or a polynucleotide encoding a coronavirus (e.g., Wuhan coronavirus (2019-nCoV; SARS-CoV-2)) protein and uses thereof. The invention also provides methods of treating and/or preventing a coronavirus (e.g., Wuhan coronavirus (2019-nCoV; SARS-CoV-2)) infection by administering an immunogenic composition or vaccine to a subject (e.g., a human). The invention also provides methods of detecting and/or monitoring a protective anti-coronavirus (e.g., Wuhan coronavirus (2019-nCoV; SARS-CoV-2)) antibody response (e.g., anti-coronavirus antibody response, e.g., anti-2019-nCoV antibody response, e.g., anti-Spike antibody response, e.g., anti-Spike neutralizing antibody response). The present invention relates to isolated nucleic and/or recombinant nucleic acid encoding a coronavirus S protein, in particular a SARS-CoV-2 S protein, and to the coronavirus S proteins, as well as to the use of the nucleic acids and/or proteins thereof in vaccines.

公开(公告)号：US20190240319A1

公开(公告)日：2019-08-08

申请号：US16385438

申请日：2019-04-16

申请人： Beth Israel Deaconess Medical Center, Inc. ,  Children's Medical Center Corporation

发明人： Stephen C. HARRISON ,  Bing CHEN ,  Dan H. BAROUCH ,  Joseph P. NKOLOLA ,  Michael Scott SEAMAN

IPC分类号： A61K39/21 ,  C12N7/00 ,  A61K39/12 ,  C07K14/005

CPC分类号： A61K39/21 ,  A61K39/12 ,  A61K2039/53 ,  A61K2039/54 ,  A61K2039/545 ,  A61K2039/55566 ,  A61K2039/575 ,  C07K14/005 ,  C12N7/00 ,  C12N2740/16051 ,  C12N2740/16122 ,  C12N2740/16134 ,  C12N2740/16171

摘要： Stabilized trimers of a clade A strain and a clade C strain of HIV-1 are provided. Broadly neutralizing antisera against HIV-1, methods of making broadly neutralizing antisera against HIV-1, broadly neutralizing vaccines against HIV-1, as well as methods of treating subjects infected with HIV, preventing HIV infection, and inhibiting HIV-mediated activities are also provided.